8-K: Lantheus Q3 2026: Strong Revenue Growth, Key Approvals, Merger Pending

Lantheus Holdings reported Q3 2026 results with a 1.5% revenue increase to $389.9 million, driven by significant growth in Neuraceq and DEFINITY, alongside key FDA approvals for TAUKLARIFY and BRAVNETSA, all while progressing towards its merger with Curium.

Summary

• Lantheus Holdings reported third quarter 2026 worldwide revenue of $389.9 million, a 1.5% increase year-over-year.
• GAAP fully diluted earnings per share decreased to $0.33 from $0.41 in Q3 2025, while adjusted fully diluted earnings per share increased to $1.68 from $1.27.
• The company received FDA approval for TAUKLARIFY (florquinitau F-18 injection) for Alzheimer's disease evaluation and final approval for BRAVNETSA (lutetium Lu 177 dotatate) for GEP-NETs.
• Lantheus entered into a definitive agreement to merge with Curium, with Curium US Holdings LLC acquiring all outstanding shares for up to $114.50 per share in cash and CVRs, representing a total transaction value of up to approximately $8.0 billion.
• Net cash provided by operating activities was $102.0 million, and free cash flow was $99.9 million for the quarter.
• Cash and cash equivalents increased to $683.6 million as of September 30, 2026, from $359.1 million at December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, primarily driven by strong growth in key products and significant regulatory approvals, despite a slight GAAP earnings dip. The pending acquisition by Curium adds a layer of strategic value and future potential.

Positives

• Worldwide revenue increased by 1.5% to $389.9 million in Q3 2026.
• Neuraceq sales saw a significant increase of 123.0% to $45.6 million.
• DEFINITY sales increased by 4.8% to $85.7 million.
• Adjusted fully diluted earnings per share (non-GAAP) increased by 32.3% to $1.68.
• FDA approval for TAUKLARIFY (florquinitau F-18 injection) for Alzheimer's disease PET imaging.
• Final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate) for GEP-NETs.
• Cash and cash equivalents significantly increased to $683.6 million.
• Entered into a definitive agreement to merge with Curium for up to $8.0 billion, offering substantial shareholder value.

Negatives

• GAAP fully diluted earnings per share decreased by 19.5% to $0.33.
• GAAP net income decreased by 19.4% to $22.4 million.
• PYLARIFY sales decreased by 0.7% to $238.9 million.
• Operating income decreased by 26.2% to $32.2 million.

Risks

• Continued market expansion, penetration, and reimbursement for established products in a competitive environment.
• Ability to complete technology transfer for PYLARIFY TruVu and obtain FDA approval for manufacturing facilities.
• Maintaining adequate coverage and payment for PYLARIFY TruVu, including timely adoption by customers.
• Availability of raw materials, key components, and equipment for product manufacturing.
• Ability to satisfy obligations under clinical development partnerships and license agreements.
• Successful integration of acquisitions, including potential unforeseen expenses and liabilities.
• Obtaining FDA approval for LNTH-2501 and successfully commercializing it.
• Timing, execution, and success of the commercialization of BRAVNETSA, including competition and ongoing litigation appeals.

Future Outlook

The company has suspended its full-year 2026 financial guidance due to the pending merger with Curium. Further development and commercialization plans for new products like TAUKLARIFY and BRAVNETSA are underway, with a focus on supporting Alzheimer's programs and preparing for commercial launches.

Management Comments

• Lantheus is the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes.
• Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries.

Industry Context

StockSavvy.ai notes that Lantheus's focus on radiopharmaceuticals, particularly in oncology and neurology, aligns with growing industry trends. The FDA approvals for TAUKLARIFY and BRAVNETSA highlight the company's innovation in addressing significant unmet medical needs in Alzheimer's disease and neuroendocrine tumors, respectively. The pending merger with Curium signals consolidation within the specialized radiopharmaceutical sector, aiming to create a larger, more integrated entity.

Legal Proceedings

• The company is dependent on POINT Biopharma Global Inc. to manufacture and supply BRAVNETSA.
• There are ongoing appeals before the U.S. Court of Appeals for the Federal Circuit related to a U.S. District Court ruling invalidating patents in Hatch-Waxman litigation.

Stakeholder Impact

• Shareholders: The pending merger with Curium offers a potential significant cash and CVR payout, representing a substantial increase in shareholder value.
• Employees: Integration with Curium may lead to changes in organizational structure and roles.
• Customers: Continued supply and access to innovative diagnostic and therapeutic radiopharmaceuticals are expected.
• Creditors: The company's strong cash position and pending acquisition provide financial stability.

Next Steps

• Continue supporting Alzheimer's disease therapeutic programs through the Pharma Solutions business.
• Assess the appropriate path toward broader commercial availability for TAUKLARIFY.
• Prepare for a thoughtful commercial launch of BRAVNETSA to support reliable supply and broad patient access.
• Complete the merger with Curium, subject to closing conditions.
• Continue development and commercialization of investigational products like LNTH-2401.

Key Dates

Recommendation

The pending acquisition by Curium at a significant premium provides a clear path to value realization for shareholders, making a 'hold' recommendation appropriate to capture the potential merger benefits. While operational results show positive trends in adjusted earnings and key product growth, the GAAP decline and ongoing integration risks warrant a cautious approach. Investors should monitor the progress of the merger and regulatory approvals.

Keywords

radiopharmaceutical, Alzheimer's disease, neuroendocrine tumors, PET imaging, PYLARIFY, TAUKLARIFY, BRAVNETSA, merger